EVH Stock Recent News

Dr. David Lim joins Evolent as chief clinical officer John Way joins Evolent as CFO, Performance Suite WASHINGTON , July 9, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced leadership additions to its clinical and financial teams, as it continues to drive innovation in specialty care. Physician, executive and startup entrepreneur Dr. David Lim has joined the company as chief clinical officer, where he will lead Evolent's 300-person medical team to support daily operations and innovation.

Evolent Health (EVH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Notes accelerating 2026 revenue bookings forecast Secures incremental non-dilutive financing WASHINGTON , June 20, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced that based on leading indicators and paid claims data through May, it continues to experience oncology cost trend below expectations coming into 2025. Evolent is reiterating its Q2 2025 Adjusted EBITDA guidance of $33M-$40M and its full year Adjusted EBITDA guidance of $135M-165M.

Evolent Health, Inc. (NYSE:EVH ) Q1 2025 Earnings Conference Call May 8, 2025 5:00 PM ET Company Participants Seth Blackley - Chief Executive Officer John Johnson - Chief Financial Officer Conference Call Participants Jack Doney - UBS Matthew Gillmor - KeyBanc Ryan Daniels - William Blair Jessica Tassan - Piper Sandler Jeff Garro - Stephens Kyle Aikman - JPMorgan Matthew Shea - Needham Constantine Davides - Citizens Charles Rhyee - TD Cowen Daniel Grosslight - Citi David Larsen - BTIG Operator Welcome to the Evolent Earning Conference Call for the First Quarter Ended March 31, 2025. As a reminder, this conference call is being recorded.

Although the revenue and EPS for Evolent Health (EVH) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Evolent Health (EVH) came out with quarterly earnings of $0.06 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.34 per share a year ago.

WASHINGTON , May 8, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended March 31, 2025. Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "Evolent Health kicked off 2025 with first quarter results at the high end of our expectations, and we are reiterating our outlook for full year 2025 revenue and Adjusted EBITDA.

The average of price targets set by Wall Street analysts indicates a potential upside of 53.3% in Evolent Health (EVH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Former CFO of CVS Health, Aetna and Coventry Health Care brings deep experience driving growth and profitability. Mr. Guertin's nomination represents continuation of Evolent's board refreshment efforts.

Program aims to achieve the best possible treatment outcomes — longer lives with fewer side-effects — without excess financial strain. Collegial provider engagement model brings together education, technology and incentives to encourage top-quality regimens.